BR112013030104A8 - Pré-formulação, processo para a formação de uma pré-formulação, método de tratamento cosmético, dispositivo de administração preenchido, e, kit - Google Patents

Pré-formulação, processo para a formação de uma pré-formulação, método de tratamento cosmético, dispositivo de administração preenchido, e, kit

Info

Publication number
BR112013030104A8
BR112013030104A8 BR112013030104A BR112013030104A BR112013030104A8 BR 112013030104 A8 BR112013030104 A8 BR 112013030104A8 BR 112013030104 A BR112013030104 A BR 112013030104A BR 112013030104 A BR112013030104 A BR 112013030104A BR 112013030104 A8 BR112013030104 A8 BR 112013030104A8
Authority
BR
Brazil
Prior art keywords
preformulation
weight
forming
kit
filled delivery
Prior art date
Application number
BR112013030104A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112013030104A2 (pt
Inventor
Catalin Nistor
Fredrik Tiberg
Markus Johnsson
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46456496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013030104(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of BR112013030104A2 publication Critical patent/BR112013030104A2/pt
Publication of BR112013030104A8 publication Critical patent/BR112013030104A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
BR112013030104A 2011-05-25 2012-05-25 Pré-formulação, processo para a formação de uma pré-formulação, método de tratamento cosmético, dispositivo de administração preenchido, e, kit BR112013030104A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161489886P 2011-05-25 2011-05-25
PCT/EP2012/059917 WO2012160213A1 (en) 2011-05-25 2012-05-25 Controlled release peptide formulations

Publications (2)

Publication Number Publication Date
BR112013030104A2 BR112013030104A2 (pt) 2016-09-20
BR112013030104A8 true BR112013030104A8 (pt) 2021-09-08

Family

ID=46456496

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013030104A BR112013030104A8 (pt) 2011-05-25 2012-05-25 Pré-formulação, processo para a formação de uma pré-formulação, método de tratamento cosmético, dispositivo de administração preenchido, e, kit

Country Status (37)

Country Link
US (3) US11433120B2 (enExample)
EP (2) EP2714004B1 (enExample)
JP (2) JP6265888B2 (enExample)
KR (1) KR102066755B1 (enExample)
CN (2) CN103702662B (enExample)
AR (1) AR086577A1 (enExample)
AU (2) AU2012260821B2 (enExample)
BR (1) BR112013030104A8 (enExample)
CA (1) CA2836847C (enExample)
CL (1) CL2013003365A1 (enExample)
CO (1) CO6900117A2 (enExample)
CR (1) CR20130653A (enExample)
CU (1) CU20130158A7 (enExample)
DK (1) DK2714004T3 (enExample)
DO (1) DOP2013000275A (enExample)
EA (1) EA036213B1 (enExample)
EC (1) ECSP13013107A (enExample)
ES (1) ES2984717T3 (enExample)
FI (1) FI2714004T3 (enExample)
GT (1) GT201300292A (enExample)
HR (1) HRP20240781T1 (enExample)
HU (1) HUE067389T2 (enExample)
IL (1) IL229376B (enExample)
LT (1) LT2714004T (enExample)
MX (1) MX361716B (enExample)
MY (1) MY177820A (enExample)
NI (1) NI201300127A (enExample)
PE (1) PE20141484A1 (enExample)
PH (1) PH12013502550B1 (enExample)
PL (1) PL2714004T3 (enExample)
PT (1) PT2714004T (enExample)
RS (1) RS65702B1 (enExample)
SG (1) SG194865A1 (enExample)
SI (1) SI2714004T1 (enExample)
TW (1) TWI624271B (enExample)
WO (1) WO2012160213A1 (enExample)
ZA (1) ZA201309653B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06014095A (es) * 2004-06-04 2007-08-07 Camurus Ab Formulaciones de deposito de lipidos.
WO2013151771A1 (en) 2012-04-05 2013-10-10 Massachusetts Institute Of Technology Immunostimulatory compositions and methods of use thereof
IN2014DN09831A (enExample) * 2012-05-25 2015-08-07 Camurus Ab
PL2877155T3 (pl) 2012-07-26 2021-05-17 Camurus Ab Formulacje opioidowe
EA034855B1 (ru) 2012-07-26 2020-03-30 Камурус Аб Предшественник депо-препарата, содержащий бупренорфин, и способ лечения путем его введения
US10300145B2 (en) 2016-07-15 2019-05-28 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
IL265270B (en) 2016-09-15 2022-09-01 Camurus Ab Prostacyclin analog formulations
IL295457A (en) 2016-09-27 2022-10-01 Camurus Ab Mixtures and formulations containing alkyl ammonium salt edta
BR112019011053A2 (pt) 2016-12-07 2019-10-15 Ra Pharmaceuticals Inc moduladores da atividade do complemento
SG11202004373RA (en) * 2017-11-15 2020-06-29 Rhythm Pharmaceuticals Inc Sustained release peptide formulations
UA128863C2 (uk) 2018-03-02 2024-11-13 Елісіо Терапьютикс, Інк. СПОЛУКА, ЯКА МІСТИТЬ CpG-ОЛІГОДЕЗОКСИНУКЛЕОТИД
CN109091451B (zh) * 2018-09-10 2021-08-13 武汉百纳礼康生物制药有限公司 亲水性药物的油相液晶凝胶前体制剂及其制备方法
WO2020191305A2 (en) 2019-03-20 2020-09-24 Massachusetts Institute Of Technology Uses of amphiphiles in immune cell therapy and compositions therefor
MX2021014450A (es) * 2019-05-29 2022-01-06 Camurus Ab Composiciones de liberacion controlada de lipidos.
CN113368041B (zh) * 2020-07-17 2023-01-03 丽珠医药集团股份有限公司 药物组合物、缓释制剂及其制备方法
MX2023013060A (es) * 2021-05-04 2023-11-15 Camurus Ab Composiciones y metodos para el tratamiento de tumores neuroendocrinos.
WO2024263085A1 (en) * 2023-06-20 2024-12-26 Camurus Ab Compositions and methods for treating acromegaly
WO2025229402A1 (en) 2024-05-02 2025-11-06 Camurus Ab Lipid compositions and methods of use thereof
WO2025229403A1 (en) 2024-05-02 2025-11-06 Camurus Ab Lipid compositions and methods of use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1682091T3 (en) * 2003-11-07 2017-05-15 Camurus Ab COMPOSITIONS OF LIPIDS AND CATIONIC PEPTIDES
MXPA06014095A (es) 2004-06-04 2007-08-07 Camurus Ab Formulaciones de deposito de lipidos.
GB0412530D0 (en) * 2004-06-04 2004-07-07 Camurus Ab Formulation
PL1778187T3 (pl) 2004-08-04 2012-09-28 Camurus Ab Kompozycje tworzące nielamelarne dyspersje
GB0417388D0 (en) * 2004-08-04 2004-09-08 Camurus Ab Composition
JP5171262B2 (ja) * 2005-01-14 2013-03-27 カムルス エービー ソマトスタチン類似体製剤
ATE462409T1 (de) * 2005-01-14 2010-04-15 Camurus Ab Topische bioadhäsive formulierungen
CA2595385C (en) * 2005-01-21 2011-01-25 Camurus Ab Pharmaceutical lipid compositions
AU2006235183B2 (en) * 2005-04-08 2011-02-10 Amylin Pharmaceuticals, Llc Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent
CA2609810C (en) * 2005-06-06 2012-05-22 Camurus Ab Glp-1 analogue formulations
GB0711656D0 (en) * 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) * 2007-08-22 2007-10-03 Camurus Ab Formulations
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations
US8931272B2 (en) * 2010-10-29 2015-01-13 Ford Global Technologies, Llc Method and system for limiting output of a boosted engine
CN104093399B (zh) * 2011-12-05 2018-03-13 卡穆鲁斯公司 鲁棒性控释肽制剂
IN2014DN09831A (enExample) * 2012-05-25 2015-08-07 Camurus Ab
US20230285502A1 (en) * 2016-09-07 2023-09-14 Camurus Ab Mixtures and formulations
IL295457A (en) * 2016-09-27 2022-10-01 Camurus Ab Mixtures and formulations containing alkyl ammonium salt edta

Also Published As

Publication number Publication date
DK2714004T3 (da) 2024-06-10
SG194865A1 (en) 2013-12-30
HUE067389T2 (hu) 2024-10-28
CU20130158A7 (es) 2014-04-24
IL229376A0 (en) 2014-01-30
GT201300292A (es) 2014-08-05
EP4427814A3 (en) 2024-11-20
US20140162944A1 (en) 2014-06-12
US20250121035A1 (en) 2025-04-17
CN103702662A (zh) 2014-04-02
EA036213B1 (ru) 2020-10-14
FI2714004T3 (fi) 2024-07-15
PL2714004T3 (pl) 2024-08-19
SI2714004T1 (sl) 2024-07-31
PE20141484A1 (es) 2014-10-31
MX2013013401A (es) 2013-12-12
MY177820A (en) 2020-09-23
ZA201309653B (en) 2016-05-25
JP2018076327A (ja) 2018-05-17
CO6900117A2 (es) 2014-03-20
NI201300127A (es) 2014-02-25
KR102066755B1 (ko) 2020-01-15
TWI624271B (zh) 2018-05-21
DOP2013000275A (es) 2014-05-15
MX361716B (es) 2018-12-14
EP2714004A1 (en) 2014-04-09
PH12013502550A1 (en) 2015-08-10
JP2014520090A (ja) 2014-08-21
CR20130653A (es) 2014-03-05
HRP20240781T1 (hr) 2024-09-13
EP2714004B1 (en) 2024-05-15
EP4427814A2 (en) 2024-09-11
CL2013003365A1 (es) 2014-07-25
CA2836847C (en) 2021-06-29
US11433120B2 (en) 2022-09-06
AU2012260821B2 (en) 2016-01-07
BR112013030104A2 (pt) 2016-09-20
CN108283619B (zh) 2021-09-14
RS65702B1 (sr) 2024-07-31
AU2016202156B2 (en) 2018-03-22
ES2984717T3 (es) 2024-10-30
CN103702662B (zh) 2018-07-20
NZ617828A (en) 2016-11-25
LT2714004T (lt) 2024-08-12
CN108283619A (zh) 2018-07-17
EA201391675A1 (ru) 2014-08-29
US20210308226A1 (en) 2021-10-07
TW201249463A (en) 2012-12-16
IL229376B (en) 2019-11-28
KR20140045438A (ko) 2014-04-16
AU2016202156A1 (en) 2016-04-28
JP6415673B2 (ja) 2018-10-31
PT2714004T (pt) 2024-07-12
PH12013502550B1 (en) 2015-08-10
AR086577A1 (es) 2014-01-08
WO2012160213A1 (en) 2012-11-29
ECSP13013107A (es) 2015-03-31
CA2836847A1 (en) 2012-11-29
JP6265888B2 (ja) 2018-01-24

Similar Documents

Publication Publication Date Title
BR112013030104A8 (pt) Pré-formulação, processo para a formação de uma pré-formulação, método de tratamento cosmético, dispositivo de administração preenchido, e, kit
BR112017013471A2 (pt) Pré-formulação, formulação farmacêutica, composição de depósito, métodos para administração de um agente bioativo a um organismo humano ou não humano, para preparação de uma composição cristalina líquida, para tratamento ou profilaxia de um indivíduo animal não humano ou humano, para administração de uma pré-formulação para um sujeito que dela necessita, processo para formação de uma pré- formulação, uso de uma mistura cristalina não líquida de baixa viscosidade, dispositivo de administração pré-preenchido, e, kit.
BR112014013691A2 (pt) pré-formulação, métodos para distribuição de um agente ativo de peptídeo, para a preparação de uma composição cristalina líquida, de tratamento ou profilaxia de um sujeito, processo para a formação de uma pré-formulação, uso de uma mistura cristalina não líquida de baixa viscosidade, dispositivo de administração de pré-preenchido, e, kit
AR071123A1 (es) Composiciones para duchas y banos de inmersion
PE20160286A1 (es) DERIVADOS DE TIENO [2,3-c] PIRANO Y SUS COMPOSICIONES FARMACEUTICAS PARA EL TRATAMIENTO DE LA FIBROSIS QUISTICA
CL2016000882A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15).
BR112016002171A2 (pt) método, composição estéril e injetável e método para preparar uma composição estéril e injetável
MX2019003520A (es) Mezclas y formulacions que comprenden una sal de alquil amonio de acido etilendiaminotetraacetico (edta).
BR112015019657A8 (pt) composições tópicas, kit e método para aumentar a liberação de óxido nítrico a partir de um gel tópico anidro contendo uma macromolécula modificada de diazeniodiolato
AR083016A1 (es) Formulaciones liquidas para la agricultura con una mejor estabilidad
EA201491685A1 (ru) Препарат для инъекций
PE20150627A1 (es) Derivados de c17-alcandiilo y alquendiilo del acido oleanolico y sus metodos de uso
BR112014032695A2 (pt) formulações estáveis para injeção parenteral de fármacos de pequenas moléculas
MX2018000894A (es) Composicion de fragancia a base de agua, dispositivo de suministro de fragancia, y metodo para proporcionar un perfume de larga duracion.
BR112013028531A2 (pt) composição inseticida líquida
MX2018012941A (es) Formulaciones y metodos para tratar organismos fotosinteticos y mejorar las calidades y cantidades de los rendimientos con formulaciones de compuestos de glicano.
TN2014000483A1 (en) Somatostatin receptor agonist formulations
SV2014004796A (es) Composiciã“n de liberaciã“n controlada y mã‰todos para su uso
BR112014017628A8 (pt) Método para o controle de insetos, uso do adjuvante líquido e método para a preparação do adjuvante
HK1239563A1 (en) Controlled-release formulations
BR112018001637A2 (pt) concentrado contendo alprostadil
BR112019007749A2 (pt) fluido de estimulação de furo de poço com acidificação, método de emulsificar um agente de acidificação em um fluido de hidrocarboneto, método de emulsificar um ácido, e, método de estimular um fundo de poço

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]